Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Danaher Corp. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Danaher Corp. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
- Gross Profit Margin
- The gross profit margin exhibited a stable and high level throughout the observed periods, starting at 57.6% and increasing to peak values around 60.9% by the end of 2021. A slight decline followed in subsequent years, dropping to approximately 58.4% by the end of 2023. However, from 2024 onwards, the margin demonstrated a moderate recovery trend, reaching close to 59.7% by late 2025. Overall, the gross profit margin remained consistently strong, indicating effective cost control over the cost of goods sold relative to revenue.
- Operating Profit Margin
- Operating profit margin showed an initial increase from 22.3% to roughly 27.6% by the end of 2022, reflecting improved operational efficiency or better expense management. After this peak, a downward trend became evident, with the margin falling to around 21.8% by the end of 2023 and further declining to approximately 18.4%-20.3% by the middle of 2025. This suggests increased operating costs or other pressures affecting profitability at the operating level during recent periods.
- Net Profit Margin
- The net profit margin followed a somewhat similar pattern to the operating margin, climbing from 19.17% to a high of approximately 23.3% by early 2023. Subsequently, a steady decline occurred, returning to below 20% by the end of 2023 and further dropping to nearly 14.2%-14.4% by mid-2025. The decline here may reflect increased expenses beyond operating profit, possibly including taxes, interest, or other non-operating items impacting the bottom line.
- Return on Equity (ROE)
- Return on equity improved from an initial 11.76% to a peak of about 14.4% around late 2022, indicating stronger profitability relative to shareholders' equity during this time. However, a notable decline ensued, with ROE falling sharply to approximately 8.2% by the end of 2023 and continuing downwards to around 6.5%-6.9% by mid-2025. This reduced equity return suggests either lower net income generation or changes in equity base, impacting shareholder value creation.
- Return on Assets (ROA)
- The return on assets started at 6.3% and increased steadily to 8.55% by the end of 2022, indicating efficient asset utilization in generating profits. Subsequently, ROA declined progressively to around 5.3%-5.6% by the end of 2023, with a continued downward trend to about 4.2%-4.4% by mid-2025. This decreasing ratio signals less efficient use of assets in producing net income over time.
Return on Sales
Return on Investment
Gross Profit Margin
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Sales | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Gross profit margin = 100
× (Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024)
÷ (SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit
- The gross profit experienced fluctuations over the observed periods. It initially rose from 4,253 million USD in April 2021 to peak at 4,943 million USD by December 2021. Subsequently, it declined moderately during 2022, with values ranging around 4,500 to 4,900 million USD for most quarters. A sharper drop occurred starting in the first quarter of 2023, with gross profit falling to as low as 3,275 million USD in September 2023. From late 2023 onward, gross profit showed signs of recovery, reaching approximately 3,890 million USD by December 2024, followed by more stable levels around the mid-3,500 million USD mark into mid-2025.
- Sales
- Sales revenue followed a generally increasing trend in 2021, rising from 6,858 million USD in April to over 8,100 million USD in December 2021. The upward momentum continued into early 2022 but with less pronounced growth, fluctuating between 7,600 and 8,300 million USD. In 2023, sales experienced a significant downturn, dropping below 6,000 million USD by the end of the first quarter and reaching a low point of approximately 5,600 million USD in September 2023. From late 2023 onwards, sales gradually improved, albeit not reaching the previous peak levels, closing at around 6,500 million USD by December 2024, with relatively stable figures near 6,000 million USD in subsequent quarters.
- Gross Profit Margin
- The gross profit margin remained relatively stable throughout the periods observed, generally hovering near the 60% mark. The margin showed a gradual increase during 2021, peaking at about 60.95% in December 2021. Slight declines occurred through 2022 and into 2023, with margins falling closer to 58.7% by September 2023. However, from late 2023 through mid-2025, the margin regained strength, stabilizing around 59.5% and remaining consistent within a narrow band between 58.4% and 60.0%. This indicates sustained profitability efficiency relative to sales despite fluctuations in absolute profit and sales values.
- Overall Insights
- The data reflect a period of growth followed by a downturn beginning in early 2023, affecting both gross profit and sales substantially. Despite the reductions in absolute terms, the gross profit margin remained fairly steady, indicating that cost management relative to revenue held consistent. The recovery trend observed from late 2023 onwards suggests improved operational performance or market conditions, although sales and profits have yet to return to the peak levels recorded at the end of 2021. This pattern may warrant further investigation into the factors contributing to the mid-period declines and the drivers behind the gradual recovery.
Operating Profit Margin
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Operating profit | |||||||||||||||||||||||||
| Sales | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Operating profit margin = 100
× (Operating profitQ3 2025
+ Operating profitQ2 2025
+ Operating profitQ1 2025
+ Operating profitQ4 2024)
÷ (SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Profit
- The operating profit exhibits significant volatility across the observed quarters. Initial quarters show a strong performance, peaking around the end of 2021 and early 2022, with values exceeding 2 billion US dollars. Following this peak, there is a notable decline in operating profit through mid to late 2023, reaching a low point near 760 million US dollars in September 2025. Some periods demonstrate partial recovery, particularly toward the end of 2024 and early 2025, but overall the trend reflects challenges in maintaining earlier profit levels.
- Sales
- Sales figures follow a somewhat fluctuating but generally stable pattern with moderate fluctuations. Starting at approximately 6.8 billion US dollars, sales grow to a peak of about 8.4 billion in late 2022. However, a marked decrease is observed from early 2023 through mid-2025, with sales dropping to around 5.7 to 6 billion US dollars. Despite this downturn, sales remain relatively steady in the most recent quarters without a clear upward rebound.
- Operating Profit Margin
- The operating profit margin initially improves during 2021 and 2022, reaching a high near 27.6%. This improvement reflects greater profitability relative to sales during that period. However, from early 2023 onward, margins progressively contract, descending from around 27% to approximately 19% by mid-2025. This decline indicates decreased efficiency or increased costs impacting earnings relative to sales levels.
- Summary and Insights
- Overall, the data reveals a peak in financial performance at the end of 2021 and early 2022, characterized by strong sales, operating profit, and margins. Subsequent quarters demonstrate a decline across these key metrics, highlighting potential operational or market challenges affecting profitability and revenue generation. While sales and operating profit margins show partial stabilization, the pronounced decrease in operating profit signals pressures on cost management or reduced operational efficiency. The downward trend in margins further emphasizes the need to investigate underlying causes for the diminished profitability despite relatively moderate sales fluctuations.
Net Profit Margin
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||||
| Sales | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
Net profit margin = 100
× (Net earningsQ3 2025
+ Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024)
÷ (SalesQ3 2025
+ SalesQ2 2025
+ SalesQ1 2025
+ SalesQ4 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in earnings, sales, and profitability over the observed periods.
- Net Earnings
- Net earnings display considerable volatility throughout the quarters examined. There is an initial peak reaching close to 1.8 billion US dollars in mid-2021, followed by a sharp decline towards the end of 2021. Earnings improve again early in 2022, reaching over 2 billion US dollars by the final quarter of that year. However, from 2023 onward, the net earnings experience a marked downward trend, punctuated by some intermittent recoveries, before falling again substantially in some quarters of 2025. Overall, net earnings exhibit fluctuations with a weakening trend visible in the later periods.
- Sales
- Sales figures also show variability but with a somewhat different pattern compared to net earnings. Sales rose steadily throughout 2021, peaking in the fourth quarter. After a slight dip and stabilization in 2022, sales exhibit a significant decline beginning in the first quarter of 2023, reaching a low point in mid-2023, followed by partial recoveries during subsequent quarters. Despite these fluctuations, sales fail to regain the highs observed in late 2021 and early 2022, indicating a downward pressure in the top-line revenue in recent periods.
- Net Profit Margin
- The net profit margin maintains a relatively high level, ranging mostly between 16% and 23%, suggesting overall effective cost management relative to sales. Margins peak towards the end of 2021 and early 2022, nearing 23%, which aligns with the periods of stronger net earnings results. However, a gradual erosion in profit margins is apparent from 2023 onwards, falling to percentages closer to 14-16% by 2025. This decline indicates increasing cost pressures or challenges in sustaining profitability despite the fluctuations in sales and earnings.
In summary, while the company experienced robust sales growth and strong earnings in 2021 and early 2022, the subsequent quarters manifest declining earnings and sales alongside diminishing profit margins. The trends suggest challenges in maintaining high profitability amid fluctuating sales, pointing to possible operational or market pressures entering the more recent periods. Management attention to cost control and revenue stabilization may be critical to reversing these downward trends.
Return on Equity (ROE)
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||||
| Total Danaher stockholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
ROE = 100
× (Net earningsQ3 2025
+ Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024)
÷ Total Danaher stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several patterns and trends in the company's performance over the observed periods.
- Net Earnings
- The net earnings exhibit considerable fluctuation across the quarters. Starting at 1,702 million USD, there is an initial increase peaking at 1,788 million USD by the end of 2021. Subsequently, earnings show volatility with a notable peak of 2,232 million USD at the end of 2022. Following this, a downward trend emerges through 2023 and into mid-2024, with values declining to a low of 555 million USD in the third quarter of 2025. A slight recovery is observed towards the end of the data range, with net earnings rising to 908 million USD.
- Total Stockholders’ Equity
- Stockholders’ equity consistently increases over the initial quarters, starting at 40,419 million USD and reaching a peak of 53,486 million USD by the end of 2023. After this peak, equity levels demonstrate some volatility with minor declines and recoveries, fluctuating around the 50,000 to 53,000 million USD range through mid-2025. This indicates relatively stable capital base with moderate variation over time.
- Return on Equity (ROE)
- ROE starts at 11.76% and generally trends upward, reaching a maximum of 14.4% in the third quarter of 2022, indicating increased profitability relative to shareholders’ equity during this period. However, from late 2022 onwards, ROE declines steadily to a low of 6.52% by the third quarter of 2025. This downward trend suggests diminishing efficiency in generating profits from equity in later periods.
Overall, the company's financial performance shows a pattern of initial growth in earnings and profitability metrics, with a subsequent period characterized by declining earnings and ROE. Meanwhile, total stockholders’ equity has increased steadily with minor fluctuations, reflecting a relatively solid equity base. The divergence between declining ROE and fluctuating net earnings, despite stable equity, may indicate challenges in sustaining profit margins or operational efficiency in recent quarters.
Return on Assets (ROA)
| Sep 26, 2025 | Jun 27, 2025 | Mar 28, 2025 | Dec 31, 2024 | Sep 27, 2024 | Jun 28, 2024 | Mar 29, 2024 | Dec 31, 2023 | Sep 29, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jul 1, 2022 | Apr 1, 2022 | Dec 31, 2021 | Oct 1, 2021 | Jul 2, 2021 | Apr 2, 2021 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net earnings | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2025-09-26), 10-Q (reporting date: 2025-06-27), 10-Q (reporting date: 2025-03-28), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-27), 10-Q (reporting date: 2024-06-28), 10-Q (reporting date: 2024-03-29), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-29), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-07-01), 10-Q (reporting date: 2022-04-01), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-01), 10-Q (reporting date: 2021-07-02), 10-Q (reporting date: 2021-04-02).
1 Q3 2025 Calculation
ROA = 100
× (Net earningsQ3 2025
+ Net earningsQ2 2025
+ Net earningsQ1 2025
+ Net earningsQ4 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Earnings
- The net earnings exhibit noticeable volatility over the observed periods. Initially, there is an upward trend from April 2021 (1702 million USD) to December 2021 (1788 million USD), followed by fluctuations throughout 2022 and early 2023. Earnings peak again at 2232 million USD in December 2022 before declining sharply to 555 million USD in September 2025. This suggests episodic profitability challenges or variable income streams impacting quarterly earnings.
- Total Assets
- Total assets show gradual growth from 75,426 million USD in April 2021 to a peak of 87,734 million USD in September 2023. Afterward, a downward trend is evident, dropping to 79,897 million USD by September 2025. This pattern indicates that asset accumulation intensified until late 2023 but later reduced, possibly due to divestitures, depreciation, or revaluation of asset holdings.
- Return on Assets (ROA)
- The ROA percentage peaks around the end of 2022 (8.55%) but has experienced a consistent decline from that point onward, reaching a low of 4.18% in June 2025 and slightly recovering to 4.38% by September 2025. This downward trajectory indicates diminishing efficiency in utilizing assets to generate earnings, matching the trend in reduced net earnings and the slight contraction in total assets.
- Overall Insights
- The financial data reveals a period of strong performance culminating in late 2022, characterized by high net earnings, asset growth, and peak ROA. Subsequently, there is a marked decline in profitability and asset base alongside reduced returns on assets. This suggests operational or market challenges affecting earnings quality and asset utilization efficiency during the latter periods. Careful attention to cost management, asset optimization, and revenue stabilization may be warranted to reverse recent negative trends.